Hypoxia-regulated protein expression, patient characteristics, and preoperative imaging as predictors of survival in adults with glioblastoma multiforme

Cancer

Volumn 113, Issue 5, 2008, Pages 1032-1042

  Flynn, Jeannette R ^a   Wang, Libo ^a   Gillespie, David L ^a   Stoddard, Gregory J ^a   Reid, Jason K ^a   Owens, Jason ^a   Ellsworth, Grant B ^a   Salzman, Karen L ^a   Kinney, Anita Y ^a   Jensen, Randy L ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Glioma; Glucose transporter 1; Hypoxia inducible factor 1 ; Microvascular density; Survival; Vascular endothelial growth factor

Indexed keywords

ANTINEOPLASTIC AGENT; CARBONATE DEHYDRATASE IX; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; VASCULOTROPIN; TUMOR MARKER;

ADULT; ARTICLE; ASTROCYTOMA; CANCER SURGERY; CANCER SURVIVAL; CELL PROLIFERATION; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DENSITY; DIAGNOSTIC IMAGING; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PREDICTION; PREDICTOR VARIABLE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SURGICAL TECHNIQUE; SURVIVAL RATE; TUMOR NECROSIS; AGED; BRAIN TUMOR; DISEASE FREE SURVIVAL; METABOLISM; MIDDLE AGED; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; CELL PROLIFERATION; DIAGNOSTIC IMAGING; DISEASE-FREE SURVIVAL; FEMALE; GLIOBLASTOMA; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 52049107208     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23678     Document Type: Article

References (42)

1. Central Brain Tumor Registry of the United States. 2001 Statistical Report: Primary Brain Tumors in the United States, 1992-1997 (years data collected). Available from URL: http://www.cbtrus.org/2001report/2001report.html
2. Baek JH, Jang JE, Kang CM, Chung HY, Kim ND, Kim KW. Hypoxia-induced VEGF enhances tumor survivability via suppression of serum deprivation-induced apoptosis. Oncogene. 2000;19:4621-4631.
3. Korkolopoulou P, Patsouris E, Kavantzas N, et al. Prognostic implications of microvessel morphometry in diffuse astrocytic neoplasms. Neuropathol Appl Neurobiol. 2002;28:57-66.
4. Sobhanifar S, Aquino-Parsons C, Stanbridge EJ, Olive P. Reduced expression of hypoxia-inducible factor-1alpha in perinecrotic regions of solid tumors. Cancer Res. 2005;65:7259-7266.
5. Korkolopoulou P, Patsouris E, Konstantinidou AE, et al. Hypoxia-inducible factor 1alpha/vascular endothelial growth factor axis in astrocytomas. Associations with microvessel morphometry, proliferation and prognosis. Neuropathol Appl Neurobiol. 2004;30:267-278.
6. Vaupel P, Kelleher DK, Hockel M. Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol. 2001;28(2 suppl 8):29-35.
7. Yetkin FZ, Mendelsohn D. Hypoxia imaging in brain tumors. Neuroimaging Clin North Am. 2002;12:537-552.
8. Brat DJ, Mapstone TB. Malignant glioma physiology: cellular response to hypoxia and its role in tumor progression. Ann Intern Med. 2003;138:659-668.
9. Lal A, Peters H, St Croix B, et al. Transcriptional response to hypoxia in human tumors. J Natl Cancer Inst. 2001;93:1337-1343.
10. Kietzmann T, Krones-Herzig A, Jungermann K. Signaling cross-talk between hypoxia and glucose via hypoxia-inducible factor 1 and glucose response elements. Biochem Pharmacol. 2002;64(5-6):903-911.
11. Carroll VA, Ashcroft M. Targeting the molecular basis for tumour hypoxia. Expert Rev Mol Med. 2005;7:1-16.
12. Mazure NM, Brahimi-Horn MC, Berta MA, et al. HIF-1: master and commander of the hypoxic world. A pharmacological approach to its regulation by siRNAs. Biochem Pharmacol. 2004;68:971-980.
13. Kaur B, Khwaja FW, Severson EA, Matheny SL, Brat DJ, Van Meir EG. Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro-Oncol. 2005;7:134-153.
14. Maxwell PH, Dachs GU, Gleadle JM, et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA. 1997;94:8104-8109.
15. Maxwell PH, Pugh CW, Ratcliffe PJ. Activation of the HIF pathway in cancer. Curr Opin Genet Dev. 2001;11:293-299.
16. Gillespie DL, Whang K, Ragel BT, Flynn JR, Kelly DA, Jensen RL. Silencing of hypoxia inducible factor-1a by RNA interference attenuates human glioma cell growth in vivo. Clin Cancer Res. 2007;13:2441-2448.
17. Heesters MA, Koudstaal J, Go KG, Molenaar WM. Analysis of proliferation and apoptosis in brain gliomas: prognostic and clinical value. J Neurooncol. 1999;44:255-266.
18. Kleihues P, Louis DN, Scheithauer BW, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol. 2002;61:215-225; discussion 226-229.
19. Sharma S, Sharma MC, Sarkar C. Morphology of angiogenesis in human cancer: a conceptual overview, histoprognostic perspective and significance of neoangiogenesis. Histopathology. 2005;46:481-489.
20. Behrem S, Zarkovic K, Eskinja N, Jonjic N. Endoglin is a better marker than CD31 in evaluation of angiogenesis in glioblastoma. Croat Med J. 2005;46:417-422.
21. Kleinschmidt-DeMasters BK, Meltesen L, McGavran L, Lillehei KO. Characterization of glioblastomas in young adults. Brain Pathol. 2006;16:273-286.
22. Leon SP, Folkerth RD, Black PM. Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer. 1996;77:362-372.
23. McKeever PE, Strawderman MS, Yamini B, Mikhail AA, Blaivas M. MIB-1 proliferation index predicts survival among patients with grade II astrocytoma. J Neuropathol Exp Neurol. 1998;57:931-936.
24. Moskowitz SI, Jin T, Prayson RA. Role of MIB1 in predicting survival in patients with glioblastomas. J Neurooncol. 2006;76:193-200.
25. Preusser M, Heinzl H, Gelpi E, et al. Histopathologic assessment of hot-spot microvessel density and vascular patterns in glioblastoma: poor observer agreement limits clinical utility as prognostic factors: a translational research project of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Cancer. 2006; 107:162-170.
26. Rodriguez-Pereira C, Suarez-Penaranda JM, Vazquez-Salvado M, et al. Value of MIB-1 labelling index (LI) in gliomas and its correlation with other prognostic factors. A clinicopathologic study. J Neurosurg Sci. 2000;44:203-209.
27. Yao Y, Kubota T, Takeuchi H, Sato K. Prognostic significance of microvessel density determined by an anti-CD105/endoglin monoclonal antibody in astrocytic tumors: comparison with an anti-CD31 monoclonal antibody. Neuropathology. 2005;25:201-206.
28. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001;95:190-198.
29. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1-8.
30. Sankoh AJ, Huque MF, Dubey SD. Some comments on frequently used multiple endpoint adjustment methods in clinical trials. Stat Med. 1997;16:2529-2542.
31. Grambsch P, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81:515-526.
32. Abdulrauf SI, Edvardsen K, Ho KL, Yang XY, Rock JP, Rosenblum ML. Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma. J Neurosurg. 1998;88:513-520.
33. Korkolopoulou P, Perdiki M, Thymara I, et al. Expression of hypoxia-related tissue factors in astrocytic gliomas. A multivariate survival study with emphasis upon carbonic anhydrase IX. Hum Pathol. 2007;38:629-638.
34. Rempel A, Mathupala SP, Griffin CA, Hawkins AL, Pedersen PL. Glucose catabolism in cancer cells: amplification of the gene encoding type II hexokinase. Cancer Res. 1996;56:2468-2471.
35. Warburg O. On the origin of cancer cells. Science. 1956;123:309-314.
36. Robey IF, Lien AD, Welsh SJ, Baggett BK, Gillies RJ. Hypoxia-inducible factor-1alpha and the glycolytic phenotype in tumors. Neoplasia. 2005;7:324-330.
37. Sallinen PK, Haapasalo HK, Visakorpi T, et al. Prognostication of astrocytoma patient survival by Ki-67 (MIB-1), PCNA, and S-phase fraction using archival paraffin-embedded samples. J Pathol. 1994;174:275-282.
38. Blouw B, Song H, Tihan T, et al. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell. 2003;4:133-146.
39. Folkerth RD. Histologic measures of angiogenesis in human primary brain tumors. Cancer Treat Res. 2004;117:79-95.
40. Barker FG, 2nd, Davis RL, Chang SM, Prados MD. Necrosis as a prognostic factor in glioblastoma multiforme. Cancer. 1996;77:1161-1166.
41. Hammoud MA, Sawaya R, Shi W, Thall PF, Leeds NE. Prognostic significance of preoperative MRI scans in glioblastoma multiforme. J Neurooncol. 1996;27:65-73.
42. Pope WB, Sayre J, Perlina A, Villablanca JP, Mischel PS, Cloughesy TF. MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol. 2005;26:2466-2474.